MedTrace Logo

Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease

NCT06188260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2024-12-02

No results posted yet for this study

Summary

This is a prospective cohort study to compare subjective changes in symptoms using the Ocular Surface Disease Index (OSDI) questionnaire, following the recommended dosage of the new nanoemulsion eye drops (Systane Complete)in mild to moderate dry eye patients, and to investigate objective ocular surface changes using modern clinical instruments during the study period.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

Systane COMPLETE Lubricant Eye Drops

Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • The Hong Kong Polytechnic University

    lead OTHER

Principal Investigators

  • Thomas LAM, PhD · The Hong Kong Polytechnique University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-16
Primary Completion
2024-11-04
Completion
2024-11-04

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06188260 on ClinicalTrials.gov